5th EuropEan MolEcular IMagIng MEEtIng - ESMI

5th EuropEan MolEcular IMagIng MEEtIng – EMIM2010
PET Amyloid and Tau Ligand [18F]FDDNP uptake in early Alzheimer disease
Tauber C. (1) , Beaufils E. (1) , Kepe V. (2) , Vercouillie J. (1) , Venel Y. (1) , Baulieu J.L. (1) , Barrio J. (2) , Hommet C. (1) , Camus V. (1) ,
Guilloteau D. (1) .
(1) UMRS INSERM U930 - CNRS ERL3106 - University of Tours, France
(2) Dpt of Molecular and Medical Pharmacology, D. Geffen School of Medecine, UCLA, United States
clovis.tauber@univ-tours.fr
Introduction: The PET tracer [18F]FDDNP specifically
binds amyloid-beta plaques and tau neurofibrillary
tangles, which are typical in the development
of the Alzheimer disease (AD). We evaluated
the feasibility of a non-invasive quantification of
[18F]FDDNP to detect these proteins and discriminate
early AD patients from healthy controls (HC).
This abstract presents the preliminary results on the
currently included cohort of 4 AD and 2 controls.
Methods: All the potential subjects underwent Neuropsychological
Assessment (MMSE, Trail Making
Test, Semantic Fluency Task, Free and Cued
Recall Test, 80 item Boston Naming Test). Patients
meeting research criteria for AD and cognitively
normal controls underwent PET imaging with
2-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2naphthyl}ethylidene)malononitrile
(FDDNP) and
[18F]FDG. All subjects underwent MR 3D axial
T1 weighted imaging. FDDNP distribution volume
ratios (DVR) parametric images were generated using
Logan graphical analysis with the cerebellum
grey matter as a reference region. Regions of interest
(ROIs) were defined in the Posterior Cingulate,
Parietal, Frontal and Temporal regions. The DVR
scores were measured as the mean DVR values of
each of these regions. A global score was calculated
as the mean DVR scores of all these regions.
Results: All the AD patients had positive FDDNP
scans by visual inspection, while all the HC had negative
scans. Global values of the FDDNP-PET binding
were significantly higher (p